664 results on '"ROOBOL, A"'
Search Results
2. Reply to Borivoj Golijanin, Anthony Mega, and Dragan Golijanin’s Letter to the Editor re: Ivo I. de Vos, Sebastiaan Remmers, Renée Hogenhout, Monique J. Roobol, ERSPC Rotterdam Study Group. Prostate Cancer Mortality Among Elderly Men After Discontinuing Organised Screening: Long-term Results from the European Randomized Study of Screening for Prostate Cancer Rotterdam. Eur Urol 2024;85:74–81
3. How Can We Improve Patient-Clinician Communication for Men Diagnosed with Prostate Cancer?
4. Understanding the barriers to prostate cancer population-based early detection programs: The PRAISE-U BEST survey
5. Differences in quality of curative treatment and outcome in men with localised prostate cancer in the screening and control arms of the ERSPC Rotterdam
6. Centralized prostatectomy with intra-operative NeuroSAFE surgical margin assessment improves surgical margin control
7. Optimizing detection and prediction of prostate cancer after positive MRI and negative biopsies
8. Does prostate cancer without cribriform pattern have metastatic potential?
9. Developing and comparing prostate cancer screening specific performance indicators for PRAISE-U
10. Development of a predictive model for death amongst patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) treated with one of the approved treatment plans, on characteristics present at admission using Big data: Preliminary results from the European network of excellence for big data in prostate cancer (PIONEER)
11. The impact of prostate cancer ADT and EBRT follow-up treatment on patient-reported quality of life – results from the EUPROMS 2.0 follow-up study
12. Effect of age at first protocoled screening on long-term outcomes in prostate cancer screening: Results from a cross-sectional screening study
13. Why is there a need to re-think prostate cancer early detection?
14. Development of prostate cancer typical case presentations and their usage in OPTIMA’s guideline based decision support tool
15. AGREE II quality assessment of national and international clinical practice guidelines on prostate cancer
16. Long-term sexual health of men on active surveillance for low-risk prostate cancer – results of the Movember GAP3 consortium
17. OPTIMA prostate cancer care pathways - bridging clinical practice guidelines, real world evidence and artificial intelligence to enhance decision-making
18. Treatment free survival and the pattern of follow-up treatments after curative prostate cancer treatment, a reflection of electronic health record data
19. A COMPARISON OF MAGNETIC RESONANCE IMAGING-BASED RISK CALCULATORS TO PREDICT PROSTATE CANCER RISK IN EUROPEAN AND NORTH AMERICAN COHORTS
20. Reasons for discontinuation of active surveillance and subsequent outcome on radical prostatectomy pathology
21. Association between circulating inflammatory markers and adult cancer risk: a Mendelian randomization analysis
22. Re: Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, et al. Fifteen-Year Outcomes After Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023;388:1547–58
23. A Detailed Evaluation of the Effect of Prostate-specific Antigen–based Screening on Morbidity and Mortality of Prostate Cancer: 21-year Follow-up Results of the Rotterdam Section of the European Randomised Study of Screening for Prostate Cancer
24. Early Detection of Prostate Cancer in the European Union: Combining Forces with PRAISE-U
25. Urinary Incontinence and Sexual Function After the Introduction of NeuroSAFE in Radical Prostatectomy for Prostate Cancer
26. Interaction of MRI and active surveillance in prostate cancer: Time to re-evaluate the active surveillance inclusion criteria
27. Evaluating approaches for constructing polygenic risk scores for prostate cancer in men of African and European ancestry
28. Clinical Characterization of Patients Diagnosed with Prostate Cancer and Undergoing Conservative Management: A PIONEER Analysis Based on Big Data
29. Detailed Evaluation of Androgen Deprivation Overtreatment in Prostate Cancer Patients Compared to the European Association of Urology Guidelines Using Long-term Data from the European Randomised Study of Screening for Prostate Cancer Rotterdam
30. The Europa Uomo Patient Reported Outcome Study 2.0—Prostate Cancer Patient-reported Outcomes to Support Treatment Decision-making
31. The Patient Journey from Randomization to Detection of Prostate Cancer and Death: Results from ERSPC Rotterdam
32. Mapping European Association of Urology Guideline Practice Across Europe: An Audit of Androgen Deprivation Therapy Use Before Prostate Cancer Surgery in 6598 Cases in 187 Hospitals Across 31 European Countries
33. Relationship Between Baseline Prostate-specific Antigen on Cancer Detection and Prostate Cancer Death: Long-term Follow-up from the European Randomized Study of Screening for Prostate Cancer
34. How Well do Polygenic Risk Scores Identify Men at High Risk for Prostate Cancer? Systematic Review and Meta-Analysis
35. Updating the Rotterdam Prostate Cancer Risk Calculator with Invasive Cribriform and/or Intraductal Carcinoma for Men with a Prior Negative Biopsy
36. Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021
37. Interaction of MRI and active surveillance in prostate cancer: Time to re-evaluate the active surveillance inclusion criteria
38. Best Current Practice and Research Priorities in Active Surveillance for Prostate Cancer—A Report of a Movember International Consensus Meeting
39. A Multivariable Approach Using Magnetic Resonance Imaging to Avoid a Protocol-based Prostate Biopsy in Men on Active Surveillance for Prostate Cancer—Data from the International Multicenter Prospective PRIAS Study
40. Engineered transient and stable overexpression of translation factors eIF3i and eIF3c in CHOK1 and HEK293 cells gives enhanced cell growth associated with increased c-Myc expression and increased recombinant protein synthesis
41. Europa Uomo Patient Reported Outcome Study (EUPROMS): Descriptive Statistics of a Prostate Cancer Survey from Patients for Patients
42. Predictive Value of Cribriform and Intraductal Carcinoma for the Nomogram-based Selection of Prostate Cancer Patients for Pelvic Lymph Node Dissection
43. 917P OPTIMA: Improve care for patients with prostate, breast, and lung cancer through artificial intelligence
44. Improving Guideline Adherence in Urology
45. Causal modeling to unravel the screening effect in ERSPC: Structural equation analysis of the Dutch, Finnish and Swedish data
46. Comparing all published MRI prostate cancer risk calculators in a large 2-centre European cohort
47. How to screen elderly men for prostate cancer: A risk-based approach using data from ERSPC Rotterdam
48. A comprehensive overview of patient reported outcomes: Results from the PIONEER consortium
49. Reducing overtreatment of prostate cancer patients: Revisiting the European Association of Urology (EAU) risk group classification by using 18 years of follow-up data
50. Evaluation after 15 years of the PRIAS study: Over 10000 men on active surveillance in daily clinical practice
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.